BridgeMD
Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis.
EU CTIS ID: 2023-508284-77-00
What this study is testing
To assess the efficacy of ALXN1720 compared with placebo in the treatment of gMG based on change in MG-ADL total score
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Must be ≥ 18 years of age at the time of signing the informed consent
- "Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV "
- Positive serological test for autoantibodies against AChR.
You likely can't join if
- History of thymectomy or any other thymic surgery within 12 months prior to Screening
- Untreated thymic malignancy, carcinoma, or thymoma
- History of Neisseria meningitidis infection
- Pregnancy, breastfeeding, or intention to conceive during the course of the study
The study team makes the final eligibility decision.
Where it's taking place
- China
- United Kingdom
- Brazil
- United States
- Serbia
- Japan
- Canada
- Turkey
- Taiwan
- Korea, Republic of
- Argentina
- Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include China; United Kingdom; Brazil; United States; Serbia; Japan and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.